The Prevalence of HTLV-III/LAV Antibodies among Intravenous Drug Users Attending Treatment Programs in California: A Preliminary Report

Norman Levy, James R. Carlson, Steven Hinrichs, Nicholas Lerche, Marc Schenker, Murray B. Gardner

Research output: Contribution to journalLetter

14 Citations (Scopus)

Abstract

To the Editor: Intravenous drug use is the primary risk factor in 17 percent of the cases of acquired immunodeficiency syndrome (AIDS) reported in the United States, and intravenous drug users constitute the second largest risk group after homosexual men.1 Recently, antibodies to human T-cell lymphotropic virus Type III/lymphadenopathy-associated virus (HTLV-III/LAV) were also detected in as many as 87 percent of patients undergoing drug detoxification who did not have diagnosed AIDS.2 3 4 Most AIDS cases associated with intravenous drug use, however, have occurred in the northeastern United States, with the greatest concentration in the New York City–New Jersey area.3 Similarly, most.

Original languageEnglish (US)
Number of pages1
JournalNew England Journal of Medicine
Volume314
Issue number7
DOIs
StatePublished - Feb 13 1986

Fingerprint

HIV Antibodies
Drug Users
HIV
Acquired Immunodeficiency Syndrome
Pharmaceutical Preparations
New England
Therapeutics
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The Prevalence of HTLV-III/LAV Antibodies among Intravenous Drug Users Attending Treatment Programs in California : A Preliminary Report. / Levy, Norman; Carlson, James R.; Hinrichs, Steven; Lerche, Nicholas; Schenker, Marc; Gardner, Murray B.

In: New England Journal of Medicine, Vol. 314, No. 7, 13.02.1986.

Research output: Contribution to journalLetter

@article{244c59d8849a4dd98a04414ec3c7acf9,
title = "The Prevalence of HTLV-III/LAV Antibodies among Intravenous Drug Users Attending Treatment Programs in California: A Preliminary Report",
abstract = "To the Editor: Intravenous drug use is the primary risk factor in 17 percent of the cases of acquired immunodeficiency syndrome (AIDS) reported in the United States, and intravenous drug users constitute the second largest risk group after homosexual men.1 Recently, antibodies to human T-cell lymphotropic virus Type III/lymphadenopathy-associated virus (HTLV-III/LAV) were also detected in as many as 87 percent of patients undergoing drug detoxification who did not have diagnosed AIDS.2 3 4 Most AIDS cases associated with intravenous drug use, however, have occurred in the northeastern United States, with the greatest concentration in the New York City–New Jersey area.3 Similarly, most.",
author = "Norman Levy and Carlson, {James R.} and Steven Hinrichs and Nicholas Lerche and Marc Schenker and Gardner, {Murray B.}",
year = "1986",
month = "2",
day = "13",
doi = "10.1056/NEJM198602133140711",
language = "English (US)",
volume = "314",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "7",

}

TY - JOUR

T1 - The Prevalence of HTLV-III/LAV Antibodies among Intravenous Drug Users Attending Treatment Programs in California

T2 - A Preliminary Report

AU - Levy, Norman

AU - Carlson, James R.

AU - Hinrichs, Steven

AU - Lerche, Nicholas

AU - Schenker, Marc

AU - Gardner, Murray B.

PY - 1986/2/13

Y1 - 1986/2/13

N2 - To the Editor: Intravenous drug use is the primary risk factor in 17 percent of the cases of acquired immunodeficiency syndrome (AIDS) reported in the United States, and intravenous drug users constitute the second largest risk group after homosexual men.1 Recently, antibodies to human T-cell lymphotropic virus Type III/lymphadenopathy-associated virus (HTLV-III/LAV) were also detected in as many as 87 percent of patients undergoing drug detoxification who did not have diagnosed AIDS.2 3 4 Most AIDS cases associated with intravenous drug use, however, have occurred in the northeastern United States, with the greatest concentration in the New York City–New Jersey area.3 Similarly, most.

AB - To the Editor: Intravenous drug use is the primary risk factor in 17 percent of the cases of acquired immunodeficiency syndrome (AIDS) reported in the United States, and intravenous drug users constitute the second largest risk group after homosexual men.1 Recently, antibodies to human T-cell lymphotropic virus Type III/lymphadenopathy-associated virus (HTLV-III/LAV) were also detected in as many as 87 percent of patients undergoing drug detoxification who did not have diagnosed AIDS.2 3 4 Most AIDS cases associated with intravenous drug use, however, have occurred in the northeastern United States, with the greatest concentration in the New York City–New Jersey area.3 Similarly, most.

UR - http://www.scopus.com/inward/record.url?scp=0022577871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022577871&partnerID=8YFLogxK

U2 - 10.1056/NEJM198602133140711

DO - 10.1056/NEJM198602133140711

M3 - Letter

C2 - 3456077

AN - SCOPUS:0022577871

VL - 314

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 7

ER -